Real-time Estimate
Cboe Europe
05:56:46 2024-05-14 EDT
5-day change
1st Jan Change
562.8
SEK
+0.49%
+12.96%
+4.18%
Sales 2024 *
1.89B
174M
238M
Sales 2025 *
2.97B
273M
374M
Capitalization
32.27B
2.97B
4.07B
Net income 2024 *
349M
32.14M
43.98M
Net income 2025 *
984M
90.61M
124M
EV / Sales 2024 *
16
x
Net cash position
2024
*
2.15B
198M
270M
Net cash position
2025
*
3.28B
302M
413M
EV / Sales 2025 *
9.76
x P/E ratio 2024 *
93.9
x
P/E ratio 2025 *
33.7
x
Employees
213
Yield 2024 *
-
Yield 2025 *
-
Free-Float
53.88%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024
05-08
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.
04-16
CI
Camurus AB Announces Board Resignations
04-02
CI
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA
03-05
MT
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly
03-05
CI
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023
02-15
CI
Nordic Shares Rose Thursday; Tomra Systems Climbed Highest
02-15
DJ
Transcript : Camurus AB, 2023 Earnings Call, Feb 15, 2024
02-15
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-15
CI
Camurus AB Provides Earnings Guidance for the Full Year 2024
02-15
CI
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024
02-13
CI
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease
02-08
CI
Nordic Stocks Rose Thursday; Kinnevik Series B Topped Leaders
01-18
DJ
Nordic Shares Rose Wednesday; Filo Climbed Highest
01-10
DJ
More news
OPINIONES DE LOS ANALISTAS DEL DÍA : Acciona, Amadeus, Acs, Endesa, Ferrari, Heineken, Iberdrola, Prosegur, Salvatore Ferragamo...
03-04
AVIS D'ANALYSTES DU JOUR : Sanofi, Stellantis, Orange, STMicroelectronics, OVH, UCB, Valeo...
03-04
AVIS D'ANALYSTES DU JOUR : Alstom, Accor, Thales, Euroapi, LVMH, Ubisoft, Worldline, Pandora...
23-10-10
Les actions en mouvement : Chargeurs, Leonardo, Embracer, et d'autres
23-05-24
Actualización de las fuertes variaciones del día : SSB hace brillar a BICO, la magia de Pendragon se disipa
22-12-09
More news 1 day +0.49%
1 week +12.96%
Current month +12.51%
1 month +14.81%
3 months +3.13%
6 months +30.77%
Current year +4.18%
More quotes
Managers
Title Age Since
Chief Executive Officer
61
01-12-31
Director of Finance/CFO
51
22-01-31
Chief Tech/Sci/R&D Officer
-
23-05-31
Members of the board
Title Age Since
Chairman
75
09-12-31
Chief Executive Officer
61
01-12-31
Director/Board Member
52
20-12-31
More insiders
Date
Price
Change
Volume
24-05-14
560.5
+0.09%
16 543
24-05-13
560
-0.71%
56,123
24-05-10
564
+5.42%
168,823
24-05-08
535
+7.82%
182,304
24-05-07
496.2
+2.78%
60,698
Delayed Quote
Nasdaq Stockholm, May 14, 2024 at 05:36 am
More quotes
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
More about the company
Average target price
593.2
SEK
Spread / Average Target
+5.92%
Consensus
1st Jan change
Capi.
+4.18% 2.98B +29.98% 682B +31.83% 586B -3.52% 364B +18.59% 327B +4.07% 285B +16.53% 240B +9.39% 209B -8.79% 203B +7.09% 165B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1